Dengue is the most common arboviral disease in humans and an increasing cause of morbidity and mortality among children and adults throughout tropical settings [1]. This endemo-epidemic RNA flavivirus is primarily spread by the Aedes aegypti mosquito, whose range is steadily extending outward from the tropics [2]. A little more than a decade ago, the World Health Organization (WHO) defined three major phenotypical clinical classifications: dengue without warning signs, dengue with warning signs, and severe dengue (marked by severe plasma leakage, hemorrhage and/or organ impairment) [3]. Severe dengue is most likely when a second infection occurs with a different serotype from the first infection. Accurate estimates of how many cases of dengue occur remain difficult to make, especially given the number of clinically inapparent cases, but the number of clinically apparent cases is likely in the 50–100 million range per year [4].

中文翻译：

---

镰状细胞病患儿进行登革热疫苗接种势在必行。

登革热是人类最常见的虫媒病毒疾病，在整个热带环境中，儿童和成年人中发病率和死亡率的上升原因日益增加[1]。这种流行性RNA黄病毒主要由埃及伊蚊传播。蚊子的范围从热带地区稳步向外扩展[2]。大约十多年前，世界卫生组织（WHO）定义了三种主要的表型临床分类：无警告征兆的登革热，有警告征兆的登革热和严重登革热（以严重的血浆渗漏，出血和/或器官损害为标志）[ 3]。当第二次感染发生的血清型不同于第一次感染时，最有可能发生严重登革热。仍然难以准确估计出登革热病例的数量，特别是考虑到临床上不明显的病例数，但每年临床上明显的病例数可能在50–100百万之间[4]。